Anteris Technologies Global Corp (AVR) USD0.0001

Sell:$3.64Buy:$4.00$0.41 (12.69%)

Prices delayed by at least 15 minutes
Sell:$3.64
Buy:$4.00
Change:$0.41 (12.69%)
Prices delayed by at least 15 minutes
Sell:$3.64
Buy:$4.00
Change:$0.41 (12.69%)
Prices delayed by at least 15 minutes

Company Information

About this company

Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.

Key people

David St Denis
President, Director
Wayne G. Paterson
Chief Executive Officer, Managing Director, Director
Matthew Mcdonnell
Chief Financial Officer
Stephen Denaro
Company Secretary, Non-Executive Director
John Daniel Seaberg
Independent Chairman of the Board
Wenyi Gu
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    AVR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Medical Equipment & Supplies
  • ISIN
    US03675P1021
  • Market cap
    $128.38m
  • Employees
    136
  • Shares in issue
    36.06m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.